Abstract: A cell culture container includes, in sequence from above in the gravity direction: a culture-medium holding container; a cell holding container that holds cells and a culture medium supplied from the culture-medium holding container through a supply port provided in the top surface thereof; a waste-liquid holding container that holds the culture medium discharged from the cell holding container; and a discharge mechanism for discharging the culture medium that has exceeded a predetermined level from the cell holding container to the waste-liquid holding container.

Abstract: Embodiments of a modular tubular bioreactor system for culturing an aqueous culture of microorganisms are described herein. The tubular bioreactor may comprise culture tubes configured in a vertically spaced and horizontally staggered arrangement to optimize the application of light to the culture in phototrophic and mixotrophic cultivation.

Abstract: In some aspects, the invention relates to selectively permeable cell culture vessel storage containers and their methods of use. In some embodiments, the containers comprise a gas-permeable membrane that is selectively impermeable to water vapor.

Abstract: A culture container includes: a culture container body; a partition plate disposed in the vicinity of a bottom of the culture container body to face the bottom so that a culture region is formed as a culture region between the partition plate and the bottom; and a sample inlet/outlet provided in the culture container body, the culture region and the sample inlet/outlet communicating with each other via an opening formed adjacent to one end of the partition plate. With the culture container and a culture method using this container, a large amount of adipocytes can be cultured at one time with easy handling. Dedifferentiation of a large amount of adipocytes and removal of cells having failed to dedifferentiate can be efficiently accomplished.

Abstract: A fermentation tank having a first supply or discharge line with a first central opening arranged at the lower end of the fermentation tank for supplying or discharging a product. The fermentation tank also has a second and a third supply or discharge line, each with a centrally arranged opening for supplying or discharging a product, the three openings being arranged at different height levels. Also, a method of fermentation using the fermentation tank.

Abstract: A microfluidic device is contemplated comprising an open-top cavity with structural anchors on the vertical wall surfaces that serve to prevent gel shrinkage-induced delamination, a porous membrane (optionally stretchable) positioned in the middle over a microfluidic channel(s). The device is particularly suited to the growth of cells mimicking dermal layers.

Abstract: The subject matter of this specification can be embodied in, among other things, a method for controlling an incubator that includes receiving by a controller a temperature profile, and varying by the controller a temperature of an incubator based on the temperature profile.

Abstract: Aspects of the present invention relate to a networked cell culture incubator and to methods for operating such an incubator. In one aspect, the cell culture incubator includes a network interface for communicating with a source of parameter data utilized successfully by other incubators. The incubator receives appropriate parameter data and conducts the incubation process as prescribed by the parameter data so as to provide an improved environment for cell culture growth. The incubator may share its own parameter data with the data source for use by other incubators. The incubator and data source may share other forms of data as well.

Abstract: The present invention relates to methods and compositions for modulating glycosylation of recombinant proteins expressed by mammalian host cells during the cell culture process. Also disclosed are methods of culturing a host cell expressing a recombinant protein in a cell culture medium comprising a disaccharide or a trisaccharide, while keeping the osmolality constant.

Abstract: Provided is a cell culture support, which is a support for attaching and culturing cells, and which includes: a fibrous web which is made by accumulating fibers of a biodegradable polymer and on which a plurality of pores are formed; and a plurality of beads formed on the fibers to secure spaces through which the cells penetrate into the fibrous web and grow therein.

Abstract: It is an object of the present invention to provide a cell culture medium capable of enhancing cell growth efficiency without using feeder cells, in particular which does not comprise serum. The present invention provides a cell culture medium which comprises growth arrest-specific 6 (GAS6) and does not comprise serum.

Abstract: The present invention is directed to purified preparations of dermal mesenchymal stem cells that are characterized by the cell surface expression of the ABCB5 P-glycoprotein. The cells may be used for any purpose that mesenchymal stem cells from other course are used. For instance they may be administered to treat an organ transplant recipient to improve allograft survival or as a treatment to patients with autoimmune diseases such as multiple sclerosis and rheumatoid arthritis.

Abstract: Provided herein are methods and assays for isolating and culturing seborrheic keratosis cells ex vivo. Also provided herein are screening assays using cultured seborrheic keratosis cells and methods for treating seborrheic keratosis in a subject.

Abstract: An improved method for preparing T cell populations expressing a chimeric antigen receptor is described.

Abstract: The invention is directed to modified T cells, methods of making and using isolated, modified T cells, and methods of using these isolated, modified T cells to address diseases and disorders. In one embodiment, this invention broadly relates to TCR-deficient T cells, isolated populations thereof, and compositions comprising the same. In another embodiment of the invention, these TCR-deficient T cells are designed to express a functional non-TCR receptor. The invention also pertains to methods of making said TCR-deficient T cells, and methods of reducing or ameliorating, or preventing or treating, diseases and disorders using said TCR-deficient T cells, populations thereof, or compositions comprising the same.

Abstract: This invention relates to chimeric polypeptides comprising OX40L and Jagged-1 polypeptides and fragments thereof and their uses for treatment of autoimmune diseases.

Abstract: Methods and compositions for the discovery and production of antibodies that can be used to identify and/or isolate hematopoietic stem cells (HSCs), for example, HSCs with high reconstitution potential. Methods and compositions are further provided for the treatment of patients with hematologic or genetic disorders, patients with cardiovascular disorders, patients recovering from wounds, or patients recovering from chemotherapy or radiation exposure using HSCs or genetically modified HSCs, for example, HSCs and/or genetically modified HSCs with high reconstitution potential.

Abstract: The invention provides culture platforms, cell media, and methods of differentiating pluripotent cells into hematopoietic cells. The invention further provides pluripotent stem cell-derived hematopoietic cells generated using the culture platforms and methods disclosed herein, which enable feed-free, monolayer culturing and in the absence of EB formation. Specifically, pluripotent stem cell-derived hematopoietic cell of this invention include, and not limited to, iHSC, definitive hemogenic endothelium, hematopoietic multipotent progenitors, T cell progenitors, NK cell progenitors, T cells, NK cells, NKT cells and B cells.

Abstract: The present invention relates to the medical field, in particular to gene editing as a therapeutic approach for the treatment of metabolic diseases affecting the erythroid lineage in a mammalian subject. In invention particular embodiment it refers to the combination of cell reprograming and gene editing for PKD correction as a first example of the potential application of these advanced technologies to metabolic diseases affecting the erythroid lineage. In this sense, PKD patient-specific iPSCs were efficiently generated from PB-MNCs (peripheral blood mononuclear cells) by a SeV non-integrative system and efficiently use to treat pyruvate kinase deficiency. The gene editing strategy for PKLR gene correction was also successfully applied directly to hematopoietic progenitors.

Abstract: Ex vivo and in vivo methods of expansion of renewable stem cells, expanded populations of renewable stem cells and their uses.

Abstract: Methods of, treatments using, and devices for restoring the regenerative capability for mesenchymal stem cells and isolating and expanding a small subpopulation of less defective mesenchymal stem cells from the bone marrow stromal cells of people with decreased quality and/or quantity of mesenchymal stem cells, such as elderly people.

Abstract: Provided herein are cell compositions useful for making artificial liver constructs. The cell composition my include, in combination, (a) hepatocyte cells, (b) Kuppfer cells, (c) hepatic stellate cells, (d) sinusoidal endothelial cells, and (e) cholangiocyte cells.

Abstract: Disclosed herein are cell culture compositions, for example, pancreatic cell culture compositions, derived from dedifferentiated human reprogrammed pluripotent stem cells, such as induced pluripotent stem (iPS) cells, and methods for producing and using such cell culture compositions.

Abstract: This document provides methods and materials related to induced pluripotent stem cells. For example, induced pluripotent stem cells, compositions containing induced pluripotent stem cells, methods for obtaining induced pluripotent stem cells, and methods for using induced pluripotent stem cells are provided. In addition, methods and materials for using induced pluripotent stem cells to repair tissue (e.g., cardiovascular tissue) in vivo as well as methods and materials for using induced pluripotent stem cells to assess their therapeutic potential in appropriate animal models are provided.

Abstract: Provided is a selective method for inducing differentiation from pluripotent stem cells to enterocyte-like cells. Also provided is an excellent enterocyte-like cell expressing drug-metabolizing enzymes and drug transporters. More specifically, provided is an enterocyte-like cell having properties closer to those of primary enterocytes, which are difficult to acquire. The foregoing is achieved by adding an ALK5 inhibitor (SB431542), Wnt3a, and EGF to a culture system of definitive endoderm cells obtained by differentiation induction from pluripotent stem cells and extending a culture time. The foregoing is also achieved by introducing CDX2 gene and/or FOXA2 gene into the pluripotent stem cells or the definitive endoderm cells. The foregoing is also achieved by overlaying a basement membrane matrix on the enterocyte-like cells.

Abstract: The present disclosure provides polynucleotide cassettes, expression vectors and methods for the expression of a gene in cone cells.

Abstract: Highly antigenic yet safe vaccines against diseases caused by Paramyxoviridae viruses such as respiratory syncytial virus (RSV) are provided. The vaccines comprise attenuated Paramyxoviridae viruses with high antigenicity but which display impaired cell-to-cell transmission as a result of genetic manipulation of the gene encoding the matrix (M) protein. In the viruses, the M protein is absent or mutated to a less active form. Screening or assay systems and methods for evaluating the infectivity of mutant M proteins anf for identifying suitable M candidates for live-attenuated vaccine virus and VLP production, are also provided.

Abstract: The invention relates to retroviral producer cells comprising nucleic acid sequences encoding: gag and pol proteins; envelope protein or a functional substitute thereof; and the RNA genome of the retroviral vector particle, wherein said nucleic acid sequences are all located at a single locus within the retroviral producer cell genome.

Abstract: An agent for treating acute respiratory distress syndrome includes, as an active ingredient, a lecithinized superoxide dismutase represented by the general formula (I): SOD?(Q-B)m??(I) (wherein, SOD? represents a residue of a superoxide dismutase; Q represents a chemical crosslinking; B represents a residue of lysolecithin, in which a hydrogen atom of a hydroxyl group is removed from the lysolecithin having the hydroxyl group at the 2-position of glycerol; and m is the average number of bonds of the lysolecithin relative to one molecule of the superoxide dismutase and represents an integer of 1 or more).

Abstract: Provided herein are compositions and methods for the synthesis of the trisaccharide, isomelezitose, using genetically modified glucansucrase enzymes from representative microorganisms, including lactic acid bacteria such as Leuconostoc mesenteroides. Various modified enzymes are detailed, increasing isomelezitose yields and provide the foundation for large-scale production of isomelezitose for food, industrial and biomedical applications.

Abstract: The present invention is directed to a polymerase activity assay that produces a strong optical signal when a primer-template complex is extended to full-length product. The assay uses Cy3 as the molecular beacon and Iowa Black® RQ as the quencher. The signal-to-noise-ratio (STNR) of this donor-quencher pairing is ˜200-fold over background, which is considerably better than other donor-quencher pairs (STNRs ˜10-20-fold). The STNR allows for solution-based monitoring of polymerase activity. Because the sensor functions via Watson-Crick base pairing, the polymerase activity assay may also be used to evolve polymerases to accept xeno nucleic acids as substrates.

Abstract: The present disclosure is directed to a modified plant cell, plant tissue, plantlet, plant part, plant, and progeny thereof containing a combination of apyrase genes, including at least one modified gene and/or at least one additional apyrase gene. The disclosure is also directed to a method of making a modified plant with a modified apyrase gene and/or an additional apyrase gene. The modified plant generally exhibits at least one improved characteristic over the plant line from which it was derived. The disclosure also relates to a recombinant DNA molecule comprising a nucleotide sequence encoding an apyrase enzyme as disclosed.

Abstract: Disclosed herein are a modified sulfamidase, a composition comprising a modified sulfamidase, as well as methods for preparing a modified sulfamidase and therapeutic use of such a sulfamidase. In particular, the present disclosure relates to a modified sulfamidase comprising substantially no epitopes for glycan recognition receptors, thereby enabling transportation of said sulfamidase across the blood brain barrier of a mammal, wherein said sulfamidase has catalytic activity in the brain of said mammal.

Abstract: In some aspects, the disclosure relates to methods and compositions for delivery of proteins into mammalian cells. In some embodiments, the disclosure provides a genetically engineered bacterium that may be useful for delivery of proteins into mammalian cells. In some aspects, the disclosure relates to improved methods of bacterially-mediated protein delivery.

Abstract: A recombinant ribonuclease is disclosed. The recombinant ribonuclease is produced by introducing a recombinant DNA sequence into a host; activating expression of the recombinant DNA sequence within the host to produce the recombinant ribonuclease; and isolating the recombinant ribonuclease from the host. Additionally, a method of analyzing an RNA sequence includes digesting the RNA with a first recombinant ribonuclease to give digestion products comprising nucleotides of the RNA sequence; and analyzing the digestion products using an analytical method to provide the identity of at least some of the nucleotides. The recombinant ribonuclease includes at least one of a uridine-specific recombinant RNase MC1 and a cytidine-specific recombinant RNase Cusativin.

Abstract: The present invention relates to isolated polypeptides having cellulolytic enhancing activity and polynucleotides encoding the polypeptides, catalytic domains, cellulose binding domains and polynucleotides encoding the polypeptides, catalytic domains or cellulose binding domains. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides, catalytic domains or cellulose binding domains.

Abstract: The invention relates to a variant polypeptide having lactase activity. The invention also relates to a nucleic acid sequence encoding such a variant polypeptide, to a nucleic acid construct comprising said nucleic acid sequence, to a recombinant expression vector comprising said nucleic acid construct and to a recombinant host cell comprising said expression vector. Further, the invention relates to a method for producing a lactase variant via use of such a host cell. Also, the invention relates to a method of producing a lactase polypeptide variant. The invention further relates to a composition comprising a lactase variant, to use of such a lactase variant or to the use of a lactase variant-containing composition in the preparation of a dairy product, to a process for the production of a dairy product and to the resulting dairy product.

Abstract: Described herein are heme-binding compositions and methods relating to their use, e.g. methods of treatment of, for example, sepsis and rhabdomyolysis.

Abstract: Disclosed herein are mannanases from Paenibacillus or Bacillus spp, polynucleotides encoding the mannanases, compositions containing the mannanases, and methods of use thereof. Compositions containing mannanases are suitable for use as detergents and for cleaning fabrics and hard surfaces, as well as in a variety of other industrial applications.

Abstract: The present invention features inter alia nucleic acid molecules which encode polypeptides comprising a single chain Fc region and the polypeptides they encode. The Fc moieties of these constructs are linked by a cleavable scFc linker which is adjacent to at least one enzymatic cleavage site, e.g., an intracellular processing site. The resulting processed molecules comprise two polypeptide chains and substantially lack the extraneous amino acid sequence found in single chain Fc linker molecule. Methods of making and using these dimeric molecules are also described.

Abstract: The present disclosure relates to solutions and methods of preparing lyophilized formulations of factor Xa (fXa) antidotes. A suitable aqueous formulation suitable for lyophilization can include a fXa antidote, a solubilizing agent, a stabilizer, and a crystalline component, wherein the formulation does not collapse during lyophilization.

Abstract: Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of modulating and treating diseases associated with hyperphenylalaninemia are disclosed.

Abstract: The present invention provides engineered ligase polypeptides and compositions thereof, as well as polynucleotides encoding the engineered ligase polypeptides. The invention also provides methods for use of the compositions comprising the engineered ligase polypeptides for diagnostic and other purposes.

Abstract: The invention provides for systems, methods, and compositions for targeting nucleic acids. In particular, the invention provides non-naturally occurring or engineered DNA or RNA-targeting systems comprising a novel DNA or RNA-targeting CRISPR effector protein and at least one targeting nucleic acid component like a guide RNA.

Abstract: Described herein are embodiments relating to manipulation of populations and sex ratio in populations through DNA sequence modifications.

Abstract: The present disclosure relates to the co-expression of an endonuclease with an end-processing enzyme for the purpose of enhanced processing of the polynucleotide ends generated by endonuclease cleavage.

Abstract: The present invention provides methods for multiplex assembly of oligonucleotides.

Abstract: Methods for identifying patient specific driver mutations are provided. The methods provided identify specific patient derived markers associated with aberrant signal transduction pathways, in biological samples of a cancer patient.

Abstract: Provided are methods of producing size-selected nucleic acid libraries. The methods include contacting a nucleic acid sample and a nucleic acid binding reagent including an affinity tag, under conditions in which nucleic acids of less than a desired length are substantially bound to the nucleic acid binding reagent and nucleic acids of the desired length are substantially not bound to the nucleic acid binding reagent. The conditions include the duration of the contacting, the concentration of the nucleic acid binding reagent, or both. The methods further include separating, using the affinity tag, the nucleic acids of less than the desired length bound to the nucleic acid binding reagent from the nucleic acids of the desired length not bound to the nucleic acid binding reagent, to produce a size-selected nucleic acid library. Compositions and kits that find use, e.g., in practicing the methods of the present disclosure, are also provided.

Abstract: Provided is a method for constructing a DNA library for sequencing. The method comprises A-tailing of a single 3? end to at least a portion of blunt-end DNA fragments, and a step of blunt-end ligating the obtained DNA fragments having A tailing to the single 3? end. Also provided are a DNA library for sequencing constructed with the method and a corresponding sequencing method.